Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Beigene Ltd ADR
(NQ:
BGNE
)
201.99
+3.40 (+1.71%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Beigene Ltd ADR
< Previous
1
2
3
4
5
6
7
Next >
BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA® (Dinutuximab Beta) for Patients with High-Risk Neuroblastoma
August 17, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research on August 25, 2021
August 16, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Reports Second Quarter 2021 Financial Results
August 05, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces Plans to Build New Manufacturing and Clinical R&D Center at Princeton West Innovation Park in Hopewell, New Jersey
August 03, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces Positive Topline Results from Phase 3 SEQUOIA Trial Comparing BRUKINSA® (Zanubrutinib) to Bendamustine Plus Rituximab in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia
July 29, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces Approval in Canada of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Mantle Cell Lymphoma
July 26, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces the Approval in China of KYPROLIS® (Carfilzomib) for Injection for Adult Patients with Relapsed or Refractory Multiple Myeloma
July 09, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC)
July 07, 2021
From
BeiGene, Ltd.
Via
Business Wire
China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma
June 23, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces China NMPA Approval of BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Relapsed or Refractory Waldenström’s Macroglobulinemia
June 18, 2021
From
BeiGene
Via
Business Wire
BeiGene Announces First Patient Dosed in Global Phase 3 Trial of Anti-TIGIT Antibody Ociperlimab in Non-Small Cell Lung Cancer
June 17, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Presents Long-Term Efficacy and Safety Results from Three Pivotal Trials of BRUKINSA® (Zanubrutinib) and Tislelizumab at EHA2021
June 11, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Presents ALPINE Results at EHA2021 Demonstrating Both Efficacy and Safety Advantages of BRUKINSA® (Zanubrutinib) in Head-to-Head Comparison to Ibrutinib in Chronic Lymphocytic Leukemia
June 11, 2021
From
BeiGene, Ltd.
Via
Business Wire
Shoreline Biosciences and BeiGene Announce Strategic Worldwide Collaboration to Develop and Commercialize Genetically Modified Natural Killer (NK) Cell Therapies
June 09, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) Solid Tumors
June 07, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Presents Clinical Data from Two Pivotal Trials of Tislelizumab at the 2021 ASCO Annual Meeting
June 04, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Presents Clinical Data from Two Phase 2 Trials of Pamiparib at the 2021 ASCO Annual Meeting
June 04, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces First Presentation of the Phase 3 ALPINE Trial Comparing BRUKINSA® (Zanubrutinib) to Ibrutinib in Chronic Lymphocytic Leukemia to Be Featured in Presidential Symposium at EHA2021
June 01, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces Positive Topline Results from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
May 21, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene to Showcase Broad Clinical Portfolio at 2021 ASCO Annual Meeting
May 19, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA® (Zanubrutinib) in Marginal Zone Lymphoma
May 19, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Highlights Progress in Hematology at EHA2021 Virtual Congress
May 12, 2021
From
BeiGene, Ltd.
Via
Business Wire
China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer
May 07, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Reports First Quarter 2021 Financial Results
May 06, 2021
From
BeiGene, Ltd.
Via
Business Wire
BRUKINSA® (Zanubrutinib) Demonstrates Superior Objective Response Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation or Flutter at Interim Analysis in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia
April 28, 2021
From
BeiGene
Via
Business Wire
BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021
April 12, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021
April 11, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress
April 08, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenström’s Macroglobulinemia
April 08, 2021
From
BeiGene, Ltd.
Via
Business Wire
BeiGene Announces First Commercial Manufacturing Approval for Its State-of-the-Art Biologics Facility in Guangzhou, China
April 07, 2021
From
BeiGene, Ltd.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.